Skip to content
DataLookout
Menu

NCT07030348

Early Diagnosis of Pancreatic Cancer Duodenal Fluid-Based Biomarker Exploratory Study

StatusRecruiting
PhaseNot specified
Primary completion (estimated)

At risk: Primary completion moved 5 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 12 words
    • Primary completion pushed from Dec 31, 2026 to May 31, 2027
    • Study completion pushed from Dec 31, 2026 to Dec 31, 2027
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Identification of Biomarkers for Early Pancreatic Cancer Detection
Timeframe: Up to 1 year from baseline

Secondary (1)

External Validation Using U.S. Samples

Arms and interventions

Pancreatic Cancer Group (DP)

Participants with a biopsy with proven stage I-IV pancreatic ductal adenocarcinoma (PDAC), or with suspected pancreatic cancer on imaging and scheduled for an endoscopic ultrasound-guided pancreatic biopsy.

Non-Pancreatic Cancer Group (DC)

Participants with pancreatic cystic tumors or with acute or chronic pancreatitis, or with no evidence of a pancreatic disease

Sites

3 sites in 2 countries

United States 2, South Korea 1